# Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

> **NCT05904028** · PHASE3 · RECRUITING · sponsor: **Jaeb Center for Health Research** · enrollment: 600 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
- **DEVICE:** Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule

## Key facts

- **NCT ID:** NCT05904028
- **Lead sponsor:** Jaeb Center for Health Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-09
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05904028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05904028, "Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05904028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*